Seminars in Respiratory and Critical Care Medicine, Table of Contents Semin Respir Crit Care Med 2012; 33(05): 431-432DOI: 10.1055/s-0032-1325153 Preface Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Orphan Lung Diseases Authors Author Affiliations Jay H. Ryu 1 Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota Recommend Article Abstract Buy Article(opens in new window) Full Text References References 1 Office of Rare Diseases. http://rarediseases.info.nih.gov/ . Accessed: June 18, 2012 2 Brewer GJ. Drug development for orphan diseases in the context of personalized medicine. Transl Res 2009; 154 (6) 314-322 3 Groft SC, de la Paz MP. Rare diseases—avoiding misperceptions and establishing realities: the need for reliable epidemiological data. Adv Exp Med Biol 2010; 686: 3-14 4 Kole A, Faurisson F. Rare diseases social epidemiology: analysis of inequalities. Adv Exp Med Biol 2010; 686: 223-250 5 Collard HR, Moore BB, Flaherty KR , et al; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176 (7) 636-643 6 American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165 (2) 277-304 7 Romagnoli M, Nannini C, Piciucchi S , et al. Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders?. Eur Respir J 2011; 38 (2) 384-391 8 Ryu JH, Sekiguchi H, Yi ES. Pulmonary manifestations of immunoglobulin G4-related sclerosing disease. Eur Respir J 2012; 39 (1) 180-186 9 McCormack FX, Inoue Y, Moss J , et al; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364 (17) 1595-1606
